Presentation is loading. Please wait.

Presentation is loading. Please wait.

Implementation Considerations

Published byEileen Morgan Modified over 5 years ago

Similar presentations

Presentation on theme: "Implementation Considerations"— Presentation transcript:

1 Implementation Considerations
PhRMA DTC Principles Implementation Considerations 12/5/2018 Lucy Rose and Associates, LLC - no copying without permission

2 Lucy Rose and Associates, LLC - no copying without permission
Submit New TV Ads to FDA Companies should submit all new direct-to-consumer television advertisements to the FDA before releasing them for broadcast. How far in advance? Request for review not stated necessary What format? Storyboards, rough cut, final? Review Timing – FDA resources? How does a company/FDA define “new?” Same ad, different language? When is a “tweak” a “tweak”? 12/5/2018 Lucy Rose and Associates, LLC - no copying without permission

3 Lucy Rose and Associates, LLC - no copying without permission
Reminder Ads? DTC television advertising that identifies a product by name should clearly state the health conditions for which the medicine is approved and the major risks associated with the medicine being advertised. Essentially does away with reminder ads Assumption that all TV ads are either branded ads or disease state Only “major risks”? How does this comport with the FDA interpretation of risk communication? 12/5/2018 Lucy Rose and Associates, LLC - no copying without permission

4 Lucy Rose and Associates, LLC - no copying without permission
Benefit/Risk Balance DTC television and print advertising should be designed to achieve a balanced presentation of the benefits and risks associated with the advertised prescription medicine.  Specifically, risks and safety information in DTC television advertising should be presented in clear, understandable language, without distraction from the content, and in a manner that supports the responsible dialogue between patients and health care professionals Seems in concert with the FDA regs. Clearly states that PhRMA supports this concept FDA has taken significant action regarding minimization of safety 12/5/2018 Lucy Rose and Associates, LLC - no copying without permission

5 Lucy Rose and Associates, LLC - no copying without permission
Educational Time Companies should spend an appropriate amount of time to educate health professionals about new medicines or new therapeutic indications before beginning the first direct-to-consumer advertising campaign.  In determining “an appropriate time,” companies should consider the importance of informing patients of the new medicine, the complexity of its risk-benefit profile, and health care professionals’ knowledge of the condition being treated.  Companies should continue to educate health care professionals as additional valid information about a new medicine is obtained from all reliable sources. What does the term “valid” mean and what does this mean for off label promotion, if anything? Test of substantial evidence? What is a “reliable source?” Subjective…What does this mean for FDA and industry? 12/5/2018 Lucy Rose and Associates, LLC - no copying without permission

Download ppt "Implementation Considerations"

Similar presentations

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)

6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.

Drug Information for Consumers and Healthcare Professionals Food and Drug Law Institute Annual Meeting Alan Goldhammer, PhD Associate VP Regulatory Affairs.
An Overview of Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Risk Communication Advisory Committee May 15, 2008.

An Overview of Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Risk Communication Advisory Committee May 15, 2008.
Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.

Management of Drug Formulary Dimitry Gotlinsky Western University Managed Care Clerkship ProPharma Pharmaceutical Consultants, Inc. 06/16/06.
@ PMCQ October 14, 2003. Agenda l PAAB info l Common Review Issues l Current Initiatives l Trends.

@ PMCQ October 14, Agenda l PAAB info l Common Review Issues l Current Initiatives l Trends.
Daniel J. Isaacman, m.D., FAAP

Daniel J. Isaacman, m.D., FAAP
MEDICINES SELECTION & FORMULARY MANAGEMENT

MEDICINES SELECTION & FORMULARY MANAGEMENT
PDUFA and DTC Advertising Reviews Prior to Use Public Hearing February 16, 2007 Testimony of the Coalition for Healthcare Communication.

PDUFA and DTC Advertising Reviews Prior to Use Public Hearing February 16, 2007 Testimony of the Coalition for Healthcare Communication.
Medication Guides Nancy M. Ostrove, Ph.D. Division of Drug Marketing, Advertising, and Communications.

Medication Guides Nancy M. Ostrove, Ph.D. Division of Drug Marketing, Advertising, and Communications.
Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.

Clinical Trials — A Closer Look. The Food and Drug Administration (FDA) is the main consumer watchdog for numerous products: Drugs and biologics (prescription.
RAC Study Group Chapter 16

RAC Study Group Chapter 16
Marketing Issues for High- Selenium Products There are more questions than answers…. Cheryl Wachenheim Agribusiness and Applied Economics North Dakota.

Marketing Issues for High- Selenium Products There are more questions than answers…. Cheryl Wachenheim Agribusiness and Applied Economics North Dakota.
Critique of Research Outlines: 1. Research Problem. 2. Literature Review. 3. Theoretical Framework. 4. Variables. 5. Hypotheses. 6. Design. 7. Sample.

Critique of Research Outlines: 1. Research Problem. 2. Literature Review. 3. Theoretical Framework. 4. Variables. 5. Hypotheses. 6. Design. 7. Sample.
Assessing the Impact of a Toll-Free Number for Reporting Side Effects in Direct-to-Consumer Television Ads: Proposed Study Design Kathryn J. Aikin, Ph.D.

Assessing the Impact of a Toll-Free Number for Reporting Side Effects in Direct-to-Consumer Television Ads: Proposed Study Design Kathryn J. Aikin, Ph.D.
 I can analyze information contained on a food label.

 I can analyze information contained on a food label.
CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.

CR-1 Concluding Remarks and Risk/Benefit Summary Mace L. Rothenberg, MD Professor of Medicine Vanderbilt Ingram Cancer Center.
Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.

Direct-to-Consumer Advertising of Prescription Drugs: Looking Back, Looking Forward Kathryn J. Aikin, Ph.D. Division of Drug Marketing, Advertising and.
The Education Adjustment Program Profile – Revised.

The Education Adjustment Program Profile – Revised.
Dr. Carolyn M. Byerly Professor Department of Journalism.

Dr. Carolyn M. Byerly Professor Department of Journalism.
Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.

Direct-to-Consumer Prescription Drug Promotion Nancy M. Ostrove, Ph.D. Division of Drug Marketing, Advertising, and Communications Food and Drug Administration.

Similar presentations

Ads by Google